BACKSTORY | Trauma and tragedy in the City of Angels: covering the LA fires

Terrified residents caught in blazing neighbourhoods, influencers ignoring the ban on drones and the frightening unpredictability of the wildfires are just some of what journalists covering the fires ravaging Los Angeles for AFP have had to manage.

Terrified residents caught in blazing neighbourhoods, influencers ignoring the ban on drones and the frightening unpredictability of the wildfires are just some of what journalists covering the fires ravaging Los Angeles for AFP have had to manage.
09/01/2026 06:30
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO...

BACKSTORY │"Like a dream": AFP photographer's return to Syria

AFP photographer Sameer al-Doumy never dreamed he would be able to return to the hometown in Syria that he escaped through a tunnel seven years ago after it was besieged by Bashar al-Assad's forces.

AFP photographer Sameer al-Doumy never dreamed he would be able to return to the hometown in Syria that he escaped through a tunnel seven years ago after it was besieged by Bashar al-Assad's forces.

BACKSTORY I Arman and the war against journalists: A year of pain and loss

The killing of the brilliant young AFP journalist Arman Soldin on the front lines in Ukraine one year ago remains a uniquely traumatic event for all of us.
There is nothing more painful for a newsroom than to lose a friend and colleague in the line of fire.

By Phil Chetwynd, AFP Global News Director


Business
Higbee & Associates

AFP launches AFPTV Live, a new video offer aimed at television channels

Agence France-Presse has announced the launch of "AFPTV Live", a new service for television networks offering more than 500 live videos a year.

Agence France-Presse has announced the launch of "AFPTV Live", a new service for television networks offering more than 500 live videos a year.
Anglais

The Audio Marketplace (TAM) Website is Now Live

The European Audio Dataspace (EAD) consortium, in partnership with AFP, announces the launch of the official website for The Audio Marketplace (TAM), marking a significant milestone in the development of Europe’s first B2B digital platform dedicated to the exchange, sale, and purchase of professional audio content across multiple languages.

The European Audio Dataspace (EAD) consortium, in partnership with AFP, announces the launch of the official website for The Audio Marketplace (TAM), marking a significant milestone in the development of Europe’s first B2B digital platform dedicated to the exchange, sale, and purchase of professional audio content across multiple languages.

AFP and Italy’s Fort Bard renew their partnership with the launch of a second exhibition

Following the success of their first collaboration, AFP and Fort Bard have unveiled their latest exhibition, "Contrasts. Stories from a World on Edge," which will be on display until 20 July, 2025.

Following the success of their first collaboration, AFP and Fort Bard have unveiled their latest exhibition, "Contrasts. Stories from a World on Edge," which will be on display until 20 July, 2025.
09/01/2026 07:00
FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities

Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink™, Debiopharm’s proprietary antibody conjugation technology. The agreement enables FluoSphera to offer ...

AFP’s 2022 results: 5% growth in commercial revenues, new tensions on costs

At its meeting on 20 April 2023, AFP's Board of Directors approved the accounts for the 2022 financial year, which confirm the Agency's continued financial recovery.

At its meeting on 20 April 2023, AFP's Board of Directors approved the accounts for the 2022 financial year, which confirm the Agency's continued financial recovery.
Anglais
Subscribe to